Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Sep 16 - Sep 21
Additional BAY-87-2243 application during RT did not decrease TCD50
Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor
tasocitinib
SCH 503034
507: a subnanomolar human beta 3 adrenergic receptor agonist
AZD8055 - mTOR Inhibitor. CAS# 1009298-09-2 size:2 mg solid Additional BAY-87-2243 application during RTAZD8055, CAS No. 1009298 09 2, is a highly potent, selective and ATP competitive mTOR inhibitor (IC50 = 0. 8 nM). It has >1, 000 fold selectivity against all PI3K isoforms (, , , ) and other members of the PI3K like kinase family (ATM and DNA PK). It has no significant activity against a panel of 260 kinases at concentrations up to 10 M. AZD8055 inhibits the phosphorylation of mTORC1 downstream targets (p70S6K and 4E BP1) as well as phosphorylation of
US$ 38.00
US$ 100.00
US$ 54.00
US$ 75.00
US$ 44.00
US$ 75.00
US$ 119.00
US$ 114.00
US$ 36.00
US$ 68.00
US$ 70.00
US$ 80.00
US$ 44.00
US$ 90.00
US$ 70.00
US$ 120.00
US$ 65.00